Get the Stockscreener App
3.93
3.68%
-0.15
After Hours:
3.80
-0.13
-3.31%
Genelux Corp stock is traded at $3.93, with a volume of 215.38K.
It is down -3.68% in the last 24 hours and up +63.75% over the past month.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
See More
Previous Close:
$4.08
Open:
$4.08
24h Volume:
215.38K
Relative Volume:
1.16
Market Cap:
$135.74M
Revenue:
-
Net Income/Loss:
$-28.30M
P/E Ratio:
-3.2479
EPS:
-1.21
Net Cash Flow:
$-21.30M
1W Performance:
+16.96%
1M Performance:
+63.75%
6M Performance:
+87.14%
1Y Performance:
-64.14%
1-Day Range:
$3.77
$4.23
1-Week Range:
$3.25
$4.7373
52-Week Range:
$1.60
$11.22
Genelux Corp Stock (GNLX) Company Profile
Name
Genelux Corp
Sector
Industry
Phone
805-267-9889
Address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
3.93 | 135.74M | 0 | -28.30M | -21.30M | -1.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-24 | Initiated | Guggenheim | Buy |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Nov-27-23 | Initiated | H.C. Wainwright | Buy |
| Sep-12-23 | Initiated | Maxim Group | Buy |
| Feb-15-23 | Initiated | The Benchmark Company | Speculative Buy |
Genelux Corp Stock (GNLX) Latest News
Genelux (GNLX) Stock Price, News & Analysis - MarketBeat
We Think Genelux (NASDAQ:GNLX) Needs To Drive Business Growth Carefully - Yahoo Finance
Could Genelux's Olvi-Vec Emerge As A Powerful Tool In The Fight Against Difficult-to-treat Cancers? - RTTNews
Geode Capital Management LLC Has $749,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux director Tyree James L sells shares worth $8,511 - Investing.com India
Genelux director Tyree James L sells shares worth $8,511 By Investing.com - Investing.com Nigeria
XTX Topco Ltd Invests $59,000 in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux VP sells shares worth $14,742 By Investing.com - Investing.com Australia
Genelux CFO Zak Lourie sells $4,921 in stock By Investing.com - Investing.com Australia
Genelux's head of regulatory sells $5,873 in stock By Investing.com - Investing.com Australia
Genelux CFO Zak Lourie sells $4,921 in stock - Investing.com
Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright - Yahoo Finance
HC Wainwright Cuts Genelux (NASDAQ:GNLX) Price Target to $30.00 - Defense World
Genelux shares target cut, maintains buy rating on 3Q earnings - Investing.com
Genelux reports Q3 EPS (19c), consensus (19c) - TipRanks
Genelux Reports $6.5M Q3 Loss, Advances Lung Cancer Trials with $35.1M Cash Runway - StockTitan
Genelux Corp. Releases New Corporate Presentation - TipRanks
Genelux Corporation to Participate in Fireside Chat at the Guggenheim Inaugural Healthcare Innovation Conference - Yahoo Finance
Genelux CEO to Present at Guggenheim Healthcare Innovation Conference - StockTitan
Individual investors who hold 56% of Genelux Corporation (NASDAQ:GNLX) gained 34%, institutions profited as well - Yahoo Finance
Guggenheim Begins Coverage on Genelux (NASDAQ:GNLX) - Defense World
Guggenheim sees upside in Genelux shares, targets $8 as pivotal cancer trial progresses - Investing.com India
Brokerages Set Genelux Co. (NASDAQ:GNLX) PT at $22.33 - MarketBeat
Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp - Yahoo Finance
Genelux doses first subject in Phase II trial of NSCLC treatment - Yahoo Finance
Genelux advances NSCLC treatment with Phase 2 Olvi-Vec trial - Investing.com
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer - Yahoo Finance
Cubist Systematic Strategies LLC Takes $56,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux Co. (NASDAQ:GNLX) Shares Sold by Renaissance Technologies LLC - Defense World
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit - Yahoo Finance
Genelux announces executive departure By Investing.com - Investing.com Australia
Genelux announces executive departure - Investing.com
Point72 Asia Singapore Pte. Ltd. Acquires Shares of 20,162 Genelux Co. (NASDAQ:GNLX) - Defense World
Affinity Asset Advisors LLC Acquires New Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Highbridge Capital Management LLC Invests $1.23 Million in Genelux Co. (NASDAQ:GNLX) - Defense World
Short Interest in Genelux Co. (NASDAQ:GNLX) Decreases By 7.3% - MarketBeat
Genelux corp insider sells over $170k in company stock - Investing.com India
Genelux director Tyree James L sells shares worth over $4,400 - Investing.com India
Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells $63,134.10 in Stock - MarketBeat
Genelux corp insider sells over $196k in company stock - Investing.com
ROTH MKM analysts initates a Buy rating for Genelux Corp (GNLX) - Knox Daily
Genelux Corp insider sells $89.6k in company stock By Investing.com - Investing.com Australia
Genelux Corp insider sells $89.6k in company stock - Investing.com India
Insider Selling: Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells 42,818 Shares of Stock - MarketBeat
Genelux Corp [NASDAQ: GNLX] Sees Increase in Stock Value - Knox Daily
Genelux Corp (GNLX) Stock: A Year of Decreases and Increases - The InvestChronicle
Genelux Corp Stock (GNLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):